JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, J. M.
Right arrow Articles by Hong, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, J. M.
Right arrow Articles by Hong, K. W.

Vol. 300, Issue 3, 787-793, March 2002

Neuroprotective Effect of Cilostazol against Focal Cerebral Ischemia via Antiapoptotic Action in Rats

Jae Moon Choi, Hwa Kyoung Shin, Ki Young Kim, Jeong Hyun Lee and Ki Whan Hong

Department of Pharmacology, College of Medicine, and Research Institute of Genetic Engineering, Pusan National University, Pusan, Korea

This study examined the protective effects of cilostazol on cerebral infarcts produced by subjecting rats to 2-h occlusion of the left middle cerebral artery followed by 24-h reperfusion. The ischemic cerebral infarct consistently involved the cortex and striatum. The infarct size was significantly reduced, when rats received 10 mg/kg cilostazol intravenously 5 min or 1 h after the completion of 2-h ischemia. Cyclic AMP level was significantly elevated in the cortex of 4- and 12-h reperfusion (P < 0.01) following treatment with cilostazol (10 mg/kg, 5 min after 2-h ischemia) accompanied by decreased tumor necrosis factor-alpha level. Samples from the regions corresponding to the penumbra showed markedly reduced Bcl-2 protein level and, in contrast, high levels of Bax protein and cytochrome c release. Cilostazol decreased Bax protein and cytochrome c release and increased the levels of Bcl-2 protein. Cilostazol (10-7-10-5 M) potently and concentration dependently scavenged hydroxyl and peroxyl radicals. In conclusion, cilostazol treatment decreases ischemic brain infarction in association with inhibition of apoptotic and oxidative cell death.

0022-3565/02/3003-0787$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Fukasawa, H. Nishida, T. Sato, M. Miyazaki, and H. Nakaya
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (Cilostazol), a Phosphodiesterase Type 3 Inhibitor, Reduces Infarct Size via Activation of Mitochondrial Ca2+-Activated K+ Channels in Rabbit Hearts
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 100 - 104.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
T. Watanabe, N. Zhang, M. Liu, R. Tanaka, Y. Mizuno, and T. Urabe
Cilostazol Protects Against Brain White Matter Damage and Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion
Stroke, June 1, 2006; 37(6): 1539 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
F. Honda, H. Imai, M. Ishikawa, C. Kubota, T. Shimizu, M. Fukunaga, and N. Saito
Cilostazol Attenuates Gray and White Matter Damage in a Rodent Model of Focal Cerebral Ischemia
Stroke, January 1, 2006; 37(1): 223 - 228.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. H. Lee, K. Y. Kim, Y.-K. Lee, S. Y. Park, C. D. Kim, W. S. Lee, B. Y. Rhim, and K. W. Hong
Cilostazol Prevents Focal Cerebral Ischemic Injury by Enhancing Casein Kinase 2 Phosphorylation and Suppression of Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation in Rats
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 896 - 903.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S.-N. Wu, S.-I. Liu, and M.-H. Huang
Cilostazol, an Inhibitor of Type 3 Phosphodiesterase, Stimulates Large-Conductance, Calcium-Activated Potassium Channels in Pituitary GH3 Cells and Pheochromocytoma PC12 Cells
Endocrinology, March 1, 2004; 145(3): 1175 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Y. Kim, H. K. Shin, J. H. Lee, C. D. Kim, W. S. Lee, B. Y. Rhim, Y. W. Shin, and K. W. Hong
Cilostazol Enhances Casein Kinase 2 Phosphorylation and Suppresses Tumor Necrosis Factor-{alpha}-Induced Increased Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation and Apoptotic Cell Death in SK-N-SH Cells
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 97 - 104.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. W. Hong, K. Y. Kim, H. K. Shin, J. H. Lee, J. M. Choi, Y.-G. Kwak, C. D. Kim, W. S. Lee, and B. Y. Rhim
Cilostazol Prevents Tumor Necrosis Factor-{alpha}-Induced Cell Death by Suppression of Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation and Activation of Akt/Cyclic AMP Response Element-Binding Protein Phosphorylation
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1182 - 1190.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.